Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Absolute Bioavailability of AZD4954 in Healthy Males
NCT07812077Phase 1Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Primary completion
- Dec 2026
01
Overview
Phase 1, open-label trial of AZD4954 (2 arms), sponsored by AstraZeneca. Primary endpoints: Amount of AZD4954 excreted up to 552 hours, Fraction of dose excreted up to 552 hours and 3 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
AZD4954
Beyond the preview
Go deeper on NCT07812077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07812077.